SERUM THYROTROPHIN, PROLACTIN AND GROWTH HORMONE, RESPONSE TO TRH DURING OESTROGEN TREATMENT

1977 ◽  
Vol 84 (1) ◽  
pp. 23-35 ◽  
Author(s):  
E. Rutlin ◽  
E. Haug ◽  
P. A. Torjesen
Keyword(s):  
Growth Hormone ◽  
Human Subjects ◽  
Serum Levels ◽  
Normal Male ◽  
Oestrogen Treatment ◽  
Thyrotrophin Releasing Hormone ◽  
Basal Serum ◽  
Menopausal Women ◽  
Menstruating Women ◽  
Post Menopausal

ABSTRACT The serum levels of thyrotrophin (TSH), prolactin (PRL) and growth hormone (GH) and the response of these hormones to 500 μg thyrotrophin-releasing hormone (TRH) iv were studied in menstruating women. in post-menopausal women before and after 2 mg oestradiol valerate for 5 consecutive days, and in men on long term oestrogen treatment. Oestrogen treatment had no effect on basal serum TSH levels, which were within the normal range in all groups. The TSH response to TRH was not different in menstruating and post-menopausal women and was not changed in the latter group after oestrogen treatment. In men treated chronically with oestrogens, the TSH response to TRH was similar to that found in normal male subjects. There was no difference in basal levels of serum PRL between males and menstruating females. In the post-menopausal women, however, basal levels of serum PRL was significantly decreased, but rose during oestrogen treatment to serum levels normally found in menstruating women. In the oestrogen treated males basal serum PRL levels were significantly higher than in untreated men. The PRL response to TRH was significantly greater in females than in males, but in the oestrogen treated males the PRL response to TRH was greatly increased and almost of the same magnitude as the response in females. There was no difference in PRL response between menstruating and post-menopausal women, and oestrogen treatment of the latter group had no significant effect on the PRL response. Basal levels of serum GH did not differ between the groups. In the group of 9 post-menopausal women one subject showed a small GH response to TRH prior to oestrogen treatment, while 7 subjects showed GH responses to TRH after oestrogen treatment. In the group of 5 chronically oestrogen treated men, 2 subjects had increased serum levels of GH after TRH. Thus our data show that oestrogen administration may induce PRL release in human subjects, while oestrogens seem to play a far less important role in the regulation of GH and TSH secretion.

Changes in serum somatomedin and growth hormone concentrations after 3 weeks oestrogen substitution in post-menopausal women; a pilot study

1984 ◽  
Vol 106 (4) ◽  
pp. 527-531 ◽  
Author(s):  
S. A. Duursma ◽  
J. W. J. Bijlsma ◽  
H. C. Van Paassen ◽  
S. C. van Buul-Offers ◽  
A. Skottner-Lundin
Keyword(s):  
Growth Hormone ◽  
Pilot Study ◽  
Serum Levels ◽  
Preventive Effect ◽  
Positive Role ◽  
Menopausal Women ◽  
The Mean ◽  
Post Menopausal ◽  
Serum Gh

Abstract. Oestrogens have a preventive effect on bone loss in post-menopausal women; however, little is known about their mechanism of action. The aim of this study was to investigate the changes in somatomedins (SM) and growth hormone (GH) concentrations in serum in postmenopausal women after 3 weeks of substitution with 20 μg ethinyloestradiol. A significant decrease was observed in the mean serum levels of SM. measured by bioassay (0.66 ± 0.07 vs 0.38 ± 0.07. P < 0.01), radioimmunoassay (0.62 ± 0.08 vs 0.34 ± 0.03, P < 0.01) and radioreceptorassav (1.14 ± 0.11 vs 0.90 ± 0.09, P < 0.01). The mean serum GH concentration increased (9.4 ± 3.2 vs 16.5 ± 4.6, P < 0.01). A positive role of SM and GH in the changes of bone metabolism after oestrogen substitution in post-menopausal women is discussed.

KLINEFELTER'S SYNDROME: EFFECTS OF OESTROGEN ON GROWTH HORMONE, PROLACTIN AND THYROTROPHIN RELEASE, AND ON THYROTROPHIN AND PROLACTIN RESPONSES TO THYROTROPHIN-RELEASING HORMONE

1979 ◽  
Vol 92 (2) ◽  
pp. 347-357 ◽  
Author(s):  
Antonino Barbarino ◽  
Laura De Marinis
Keyword(s):  
Growth Hormone ◽  
Normal Male ◽  
Klinefelter’S Syndrome ◽  
Klinefelter's Syndrome ◽  
Serum Growth Hormone ◽  
Oestrogen Treatment ◽  
Thyrotrophin Releasing Hormone ◽  
Trh Stimulation ◽  
Control Serum ◽  
Normal Men

ABSTRACT In 4 normal men and 8 patients with Klinefelter's syndrome the effects of oestradiol-17 β (15μg/kg daily for 8–13 days) on serum levels of pituitary hormones were investigated. Control levels of gonadotrophins in the Klinefelter patients were significantly higher than in the normal males, whereas serum testosterone (T) levels were lower. Oestradiol induced a decrease in serum gonadotrophin concentrations in both the control subjects and the Klinefelter patients, whereas a testosterone suppression was observed in the normal subjects, but not in the Klinefelter patients. Control serum growth hormone (hGH), and prolactin (hPRL) levels were of comparable magnitude in both groups and significantly increased during oestradiol administration. Serum thyrotrophin (TSH) levels were normal before and during oestrogen treatment. Basal serum oestradiol levels were within the normal male range, and were increased during treatment. Prolactin and thyrotrophin responsiveness to TRH stimulation was examined in Klinefelter patients before and during oestrogen administration. Before treatment, hPRL responses to TRH were higher than those observed in normal men. During oestrogen treatment hPRL responses to TRH were significantly increased when compared to those observed before treatment. TSH responses to TRH were normal both before and during treatment. These studies indicate that in patients with Klinefelter's syndrome pharmacological doses of oestrogen induce different effects on the hypothalamic-pituitary axis, as regards the release of gonadotrophins, prolactin, thyrotrophin, and growth hormone, similar to those observed in normal men. This fact supports the conclusion that in Klinefelter's syndrome the abnormality in the pituitary-gonadal feedback mechanism is selectively confined to the testosterone feedback control of gonadotrophin secretion. Finally, in patients with Klinefelter's syndrome, oestrogen is capable of inducing a significant increase of the hPRL response to TRH stimulation.

Effects of calcifediol versus cholecalciferol on 25(OH)D3 serum levels, appendicular muscle strength, and physical performance in post-menopausal women

2016 ◽  
Author(s):  
Antimo Moretti ◽  
Sire Alessandro de ◽  
Dario Calafiore ◽  
Raffaele Gimigliano ◽  
Francesca Gimigliano ◽  
...  
Keyword(s):  
Muscle Strength ◽  
Physical Performance ◽  
Serum Levels ◽  
Menopausal Women ◽  
Post Menopausal

HOMOLOGOUS RADIOIMMUNOASSAY FOR CANINE PROLACTIN

1977 ◽  
Vol 85 (4) ◽  
pp. 736-743 ◽  
Author(s):  
P. J. Knight ◽  
J. M. Hamilton ◽  
C. G. Scanes
Keyword(s):  
Growth Hormone ◽  
Intravenous Injection ◽  
Cross Reaction ◽  
Normal Male ◽  
Thyrotrophin Releasing Hormone ◽  
Releasing Hormone ◽  
Standard Curve ◽  
Double Antibody

ABSTRACT A homologous double antibody radioimmunoassay has been developed for canine prolactin. Purified canine prolactin was iodinated by lactoperoxidase/H2O2 to an average of 101 ± 10.1 μCi/μg. Antiserum was used at a final dilution of 1:80 000 and at this concentration bound approximately 20% of the added tracer in the absence of competing unlabelled prolactin. Partial cross-reaction was observed with ovine and bovine prolactin but there was no cross-reaction with a highly purified canine growth hormone preparation. Dilutions of pregnant and lactating bitch sera were parallel to the purified canine prolactin standard curve. Mean prolactin levels in normal male and anoestrous females were 8.8 ± 0.8 and 12.6 ± 2.6 ng/ml, respectively. Thyrotrophin-releasing hormone (TRH) induced a consistent elevation in prolactin levels 15–30 min after intravenous injection.

Basal and TRH stimulated serum levels of TSH in patients with hyperprolactinaemia and in subjects on oestrogen treatment

1983 ◽  
Vol 102 (2) ◽  
pp. 173-178 ◽  
Author(s):  
Eva M. Erfurth ◽  
Pavo Hedner ◽  
Anders Nilsson
Keyword(s):  
Serum Level ◽  
Serum Levels ◽  
Plasma Prolactin ◽  
Thyroid Antibodies ◽  
Elevated Plasma ◽  
Oestrogen Treatment ◽  
Pituitary Dysfunction ◽  
Basal Serum ◽  
The Mean ◽  
Serum Tsh

Abstract. In 21 hyperprolactinaemic patients without other signs of pituitary dysfunction the mean basal serum level of TSH was 4.4 ± 0.47 μU/ml that was significantly (P < 0.001) higher than controls (2.5 ± 0.16 μU/ml and oestrogen treated individuals (2.4 ± 0.29 μU/ml). The TSH increase was more pronounced (P < 0.05) in hyperprolactinaemic patients without sellar enlargement and with moderately elevated plasma prolactin levels (155 ± 42 μg/ml) than in patients with sellar enlargement and higher plasma prolactin levels (857 ± 306 μg/ml). The serum levels of thyroxine and triiodothyronine in the hyperprolactinaemic patients did not differ significantly from controls. Patients with thyroid antibodies were excluded. The increased basal serum level of TSH in hyperprolactinaemia is compatible with the concept of a reduced dopaminergic tonus as the mechanism for both changes. In patients with advanced hyperprolactinaemia and sellar enlargement the high prolactin level may induce some inhibition of TSH release and explain their lower basal serum level of TSH that was probably not due to pituitary compression as they responded normally to TRH. The TSH response to TRH was significantly (P < 0.05) correlated to the basal serum TSH in all groups. The regression lines were very similar for hyperprolactinaemic patients and controls suggesting that in hyperprolactinaemia the thyrotroph has not changed its mode of response to TRH. In contrast, oestrogen treated subjects in addition to dependence on basal serum TSH levels showed a genuinely augmented response to TRH (164.6 ± 20.3%, P < 0.01) compared to controls.

scholarly journals Association of c/t polymorphism in the lrp5 gene with circulating follicle stimulating hormone in Caucasian postmenopausal women

2007 ◽  
pp. 735-739
Author(s):  
I Žofková ◽  
M Hill ◽  
K Zajíčková
Keyword(s):  
Postmenopausal Women ◽  
Sex Hormones ◽  
Restriction Analysis ◽  
Follicle Stimulating Hormone ◽  
Serum Levels ◽  
Mediating Role ◽  
Serum Lh ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Stimulating Hormone

The LRP5 gene is believed to be primarily associated with bone metabolism via Wnt signaling. The latter pathway, however, appears to control various other systems outside the skeleton. To find the relationships of the LRP5 gene to serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) in the cohort of normal postmenopausal women, we identified the C/T (c.4037:A1330V) polymorphism in the LRP5 gene using a restriction analysis of the PCR product in a cohort of 165 untreated pre- and post-menopausal women. In a subset of 111 post-menopausal women we analyzed the association between the LRP5 genotype and serum levels of sex-hormones including FSH and LH. The distribution of CC, TC and TT genotypes of the C/T polymorphism in the whole group was 73.9 %, 23.6 % and 2.4 %, respectively, which is comparable with other Caucasian populations. As no TT homozygote was found in the group of post-menopausal women, serum sex-hormones were compared between CC and TC genotypes. Women with the CT allele combination had markedly higher serum FSH levels as compared to carriers of the CC genotype (p<0.004). No differences between these genotypes were found in serum LH levels as well as the circulating sex-steroids such as estradiol, testosterone, dehydroepiandrosterone and/or its sulphate, androstenedione and SHBG. To conclude, the LRP5 gene is associated with circulating FSH in normal post-menopausal women in the present study. The mediating role of subtle undetectable variations in estrogen levels is discussed. We did not find any relationship between the LRP-5 genotype and serum LH levels.

Sign in / Sign up

Export Citation Format

Share Document